Inspira Technologies Secures Japanese Patent for Convertible Dual Lumen Cannula, Enhancing Market Position
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: Newsfilter
- Patent Grant: Inspira Technologies has been granted Patent No. 7777598 by the Japan Patent Office, covering its innovative Convertible Dual Lumen Cannula device and method of use, securing exclusive commercial rights in Japan, one of the world's most advanced medical device markets, until 2041.
- Market Protection: This patent complements the U.S. patent granted in 2023, further enhancing a unified protective barrier across two of the largest healthcare economies, laying the groundwork for potential standalone commercialization.
- Cost Efficiency Improvement: The convertible cannula design allows a single-lumen cannula to convert into a dual-lumen cannula post-insertion, potentially reducing infection risks and procedural complexities compared to traditional dual-lumen solutions, thereby lowering hospital costs and enhancing patient safety.
- Strategic Development: CEO Dagi Ben-Noon emphasized that this patented technology not only offers a more cost-effective solution but also solidifies the foundation for the company's respiratory support platforms and future disposable revenue streams, reflecting its strategic positioning within the MedTech landscape.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like IINN with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on IINN
About IINN
Inspira Technologies Oxy B.H.N Ltd, formerly Insense Medical Ltd, incorporated on February 27, 2018, is a specialty medical device company based in Israel. The Company is engaged in the research, development, manufacture, and marketing of respiratory support technology that is intended to provide an alternative to invasive mechanical ventilation (MV). It provides patients with acute respiratory distress syndrome to maintain spontaneous breathing and avoid the various risks associated with the use of MV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inspira Technologies Achieves Major Milestone in U.S. Hospital
- Clinical Evaluation Completed: Inspira's INSPIRA™ ART100 system has completed its clinical evaluation at a leading U.S. academic medical center, successfully treating approximately 30 patients, marking its transition from pilot use to standard clinical workflow and significantly enhancing the company's recognition in the medical device market.
- Procurement Process Initiated: The medical center has initiated an internal procurement process for multiple ART100 systems, indicating that the technology's clinical value and reliability have been thoroughly validated, which is expected to drive broader adoption of ART100 across other healthcare institutions.
- Technology Validation: The ART100 system is the first to progress from clinical evaluation to a budgeted procurement pathway at a major U.S. academic medical center, reflecting Inspira's competitiveness and market potential in the medical device sector, thereby strengthening its commercial positioning.
- Future Development Outlook: Inspira CEO Dagi Ben-Noon stated that this milestone will facilitate the broader adoption of the ART100 platform across leading healthcare institutions, further solidifying the company's market position in life support and MedTech.
Continue Reading
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
Continue Reading